Document is current
Any future updates will be listed below
-
Authors
Tansey, Ryann https://orcid.org/0000-0002-6865-5893
Perini, Irene https://orcid.org/0000-0002-5972-0913
Petrie, Gavin N. https://orcid.org/0000-0003-3391-6747
Haggarty, Connor J. https://orcid.org/0000-0001-6678-0570
Mazurka, Raegan https://orcid.org/0000-0002-4974-4815
Yngve, Adam https://orcid.org/0000-0003-1012-7286
Mina, Sarah
Jones, Madeleine R.
Engelbrektsson, Hilda
Capusan, Andrea J. https://orcid.org/0000-0003-1758-2206
Hill, Matthew N.
Heilig, Markus https://orcid.org/0000-0003-2706-2482
Mayo, Leah M. https://orcid.org/0000-0002-0645-4869
- License Information
-
More Information
Article History
Received: 3 June 2025
Revised: 13 December 2025
Accepted: 28 January 2026
First Online: 6 February 2026
Competing interests
: MH received clinical trial materials and funding from Janssen Pharmaceutica NV for work related to this trial. MH has also received consulting fees, research support or other compensation from Indivior, Camurus, Molteni, BrainsWay, Aelis Farma, and Lundbeck. AJC has received consulting fees from Indivior, Camurus, Lundbeck, and DNEPharma. LMM has received consulting fees from Synendos Therapeutics. All other authors report no other disclosures or conflicts of interest.
: This clinical trial (EudraCT 2020-001965-36) was approved by and conducted according to the regulations of the Swedish Ethical Review Authority (Dnr 2020-57043) and the Swedish Medical Products Agency.
